Early neurophysiology and pressure-flow research directly underpin modern urodynamics, whereas Turner-Warwick's restorative philosophy, according to Sasha Vereecken, BScN, RN. A phase 1 study found ...

"Patient perception is an important aspect of developing an effective treatment plan, and we should be able to arm patients with accurate data to help them make an informed decision," write Whitney ...

Experts discuss the implications of the FDA’s potential pathway to expand testosterone replacement therapy labeling for low libido in men with idiopathic hypogonadism.

"If a high percentage of the radicals are billed with urethral suspension, then it is likely to be bundled in the future and it is possible that it will be tagged with an indicator that will not allow ...

"The patient’s counsel alleged that the urologist had failed to properly inform the patient of the risks and complications associated with the treatment," writes Acacia Brush Perko, Esq. On August 22, ...

The ZIRCON trial reported high accuracy of TLX250-CDx in detecting and characterizing ccRCC in patients with indeterminate renal masses. Data from the phase 3 ZIRCON trial (NCT03849118) evaluating ...

Although the overall incidence of prostate cancer has declined, the percentage of patients with metastatic disease at diagnosis has increased over the last decade. Over the past decade, the incidence ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

The FDA authorized an Expanded Access Program for NAI to manage lymphopenia in refractory or relapsed solid tumor patients. ImmunityBio’s Cancer BioShield platform enhances NK and T cell proliferation ...

Pasritamig targets KLK2 and has FDA fast track designation for mCRPC, enabling accelerated development and review processes. Phase 1 study showed pasritamig was well-tolerated with promising antitumor ...

A nurse practitioner discusses how she supports multiple providers in a large academic practice.

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...